BREAST CANCER RESEARCH NEWS: WHAT YOU NEED TO KNOW November 2020
FDA Approves Immunotherapy Keytruda for PD-L1-Positive Triple-Negative Breast Cancer Last week Keytruda was approved in combination with chemotherapy to treat locally advanced or metastatic triple-negative, PD-L1-positive breast cancer that can’t be removed with surgery. Results from a clinical trial showed that the treatment combination offered better progression-free survival than chemotherapy alone.
Breast Cancers Found Between Regular Screening Mammograms Seem More Aggressive Researchers looked at information from 69,025 women who were part of the national breast cancer screening program in Manitoba, Canada, from January 2004 to June 2010. According to the study,
interval cancers were more likely to have aggressive characteristics than breast cancers found by routine screening. Read
Study: Older Women With Early-Stage HER2-Positive Breast Cancer May Be Able to Skip Chemotherapy Researchers wanted to see if treating certain women aged 70 to 80 with Herceptin alone after surgery offered the same benefits as treating them with Herceptin plus chemotherapy because this age group has a higher risk of side effects from chemotherapy. Read
Better Survival for Early-Stage HER2-Positive Breast Cancer Linked to Pathologic Complete Response to Targeted Therapy Before Surgery Women diagnosed with early-stage HER2-positive breast cancer treated with Herceptin and Tykerb before surgery who had a
pathologic complete response (pCR) had better survival than women who didn’t have a pCR. Read
Early Results Suggest Ibrance Plus Faslodex as First Treatment Improves Outcomes for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer The Ibrance and Faslodex treatment combination
improved progression-free survival compared to Faslodex alone, according to the FLIPPER study. The early results are encouraging, but more research is needed to see if this improvement translates into better overall survival. Read
The Breastcancer.org
research news update is sponsored by Lilly Oncology.
